Corporate StrategyA corporate reduction in force, including the commercial organization, was undertaken in advance of the merger, contributing to a lower outlook.
Financial PerformanceThe company's third quarter reflected a top-line miss, and the full-year 2024 guidance was reduced at the midpoint, indicating ongoing challenges.
Revenue And SalesSTIM missed estimates with Q3/24 revenue of $18.5M, below both the analyst's estimate and consensus, driven by a miss in treatment session revenue.